Literature DB >> 2803908

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

D J Kerr1, T Maughan, E Newlands, G Rustin, N M Bleehen, C Lewis, S B Kaye.   

Abstract

Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in either disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2803908      PMCID： PMC2247346          DOI： 10.1038/bjc.1989.230

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours.

Authors:  G P Smith; S B Calveley; M J Smith; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1987-08

2.  Immune thrombocytopenia caused by flavone-8-acetic acid.

Authors:  H P Davis; E S Newlands; T Allain; U Hegde
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

3.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

4.  Phase I and pharmacokinetic study of flavone acetic acid.

Authors:  D J Kerr; S B Kaye; J Cassidy; C Bradley; E M Rankin; L Adams; A Setanoians; T Young; G Forrest; M Soukop
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

5.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.

Authors:  R L Hornung; H A Young; W J Urba; R H Wiltrout
Journal:  J Natl Cancer Inst       Date:  1988-10-05       Impact factor: 13.506

7.  Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo.

Authors:  M C Bissery; F A Valeriote; G G Chabot; J D Crissman; C Yost; T H Corbett
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

8.  Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy.

Authors:  J L Evelhoch; M C Bissery; G G Chabot; N E Simpson; C L McCoy; L K Heilbrun; T H Corbett
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).

Authors:  D J Kerr; S B Kaye; J Graham; J Cassidy; M Harding; A Setanoians; J C McGrath; W R Vezin; D Cunningham; G Forrest
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701
  9 in total
  19 in total

1.  Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

Authors:  Guanjun Cheng; Jing Sun; Zvi G Fridlender; Liang-Chuan S Wang; Lai-Ming Ching; Steven M Albelda
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

2.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.

Authors:  Minh Hien Pham; Hervé Rhinn; Nicolas Auzeil; Anne Regazzetti; Djamel Eddine Harami; Daniel Scherman; Guy G Chabot
Journal:  Drug Metab Lett       Date:  2011-04

4.  Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

Authors:  M de Forni; G G Chabot; J P Armand; A Gouyette; M Klink-Alak; G Recondo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 7.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 8.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.

Authors:  Zachary J Roberts; Nadege Goutagny; Pin-Yu Perera; Hiroki Kato; Himanshu Kumar; Taro Kawai; Shizuo Akira; Ram Savan; David van Echo; Katherine A Fitzgerald; Howard A Young; Lai-Ming Ching; Stefanie N Vogel
Journal:  J Exp Med       Date:  2007-06-11       Impact factor: 14.307

10.  Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.

Authors:  T S Maughan; R Ward; I Dennis; D J Honess; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.